ENDRA Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Business Wire•16/11/2026•16:44 ET
1
Key Highlights
- ➤Proposed Noble Africa merger would make it ENDRA’s wholly owned subsidiary and rename ENDRA 4K Resources
- ➤Concurrent Noble Africa private placement expected to generate approximately $50 million gross proceeds
- ➤Merger closing remains subject to stockholder approval, Form S-4 effectiveness, and Nasdaq requirements
- ➤Third-quarter cash used in operations rose to $1.8 million from $1.2 million
- ➤September 30 unrestricted cash totaled $1.5 million, alongside $3.4 million restricted cash
Expert Statements
Alexander Tokman, Chairman and Chief Executive Officer of ENDRA Life Sciences
“Our focus during the third quarter remained on completing the proposed merger with Noble Africa while managing ENDRA's operating resources and liquidity to support transaction-related priorities. The proposed transaction represents an important strategic opportunity for our stockholders. We continue to work with our merger counterparties to complete the remaining steps necessary to close the merger.”
ENDRA Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the third quarter ended September 30, 2026, and provided a business update.
Get started
Create a free account to read the full story.
